Evidence map›Paper›PMID 35033862›Full record

ArticleThrombosis research2022

Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation.

Vanessa Innao, Salvatore Urso, Monica Insalaco, Albino Borraccino, Ugo Consoli

Abstract readLetter
In one paragraph

Article in Thrombosis research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. COVID-19 and HSCT (Hematopoietic stem cell transplant).Best practice & research. Clinical haematology · 2022
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vanessa InnaoU.O.C di Ematologia, Azienda ospedaliera di rilievo nazionale e di alta specializzazione, ARNAS - Garibaldi di Catania, Catania, Italy. Electronic address: vanessainnao@gmail.com.
Salvatore UrsoU.O.C. di Nefrologia, Azienda ospedaliera di rilievo nazionale e di alta specializzazione, ARNAS - Garibaldi di Catania, Catania, Italy.
Monica InsalacoU.O.C. di Nefrologia, Azienda ospedaliera di rilievo nazionale e di alta specializzazione, ARNAS - Garibaldi di Catania, Catania, Italy.
Albino BorraccinoU.O.C. di Anestesia e Rianimazione, Azienda ospedaliera di rilievo nazionale e di alta specializzazione, ARNAS - Garibaldi di Catania, Catania, Italy.
Ugo ConsoliU.O.C di Ematologia, Azienda ospedaliera di rilievo nazionale e di alta specializzazione, ARNAS - Garibaldi di Catania, Catania, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationLymphomaPurpura, Thrombotic ThrombocytopenicADAMTS13 ProteinHumansVaccinationADAMTS13 ProteinADAMTS13Covid-19Thrombotic microangiopathyThrombotic Thrombocytopenic PurpuraVaccination

Identifiers

PMID35033862
PMCPMC8723754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.